Group vs individual MDMA therapy for PTSD after Oct 7
Part of Mental health clinical trials.
This study compares MDMA-assisted therapy in a group setting versus individual sessions for people whose PTSD started after the October 7, 2023 events in Israel. You would receive MDMA along with therapy sessions to see which format works best for reducing PTSD symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have been diagnosed with PTSD after October 7, 2023, related to those events.
- You need to have at least moderate PTSD symptoms in the past month.
- You must speak and read Hebrew fluently.
- You must have a support person (like a family member or friend) who can be reached if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether MDMA (a drug that can help people feel safe and open during therapy) combined with talk therapy can reduce PTSD symptoms in active-duty service members, National Guard, and Reserve members. If you are struggling with PTSD that has lasted at least 6 months, this trial may offer a new treatment option.
This Phase 2 study tests whether MDMA combined with therapy that uses exposure (gradual confronting of trauma memories) can reduce PTSD symptoms. It may help people who meet PTSD criteria, can follow strict safety rules, and can complete medicine-session monitoring.
This Phase 2 study compares MDMA-assisted Cognitive Processing Therapy (a structured talk-therapy) to Cognitive Processing Therapy alone for Veterans with severe PTSD. It aims to see whether adding MDMA helps reduce PTSD symptoms and improve recovery.
This study tests if psilocybin-assisted group therapy can help people with moderate to severe PTSD. It is for veterans, first responders, female survivors of sexual violence, or Indigenous individuals.
This study tests whether a drug called psilocybin (the active ingredient in 'magic mushrooms') combined with therapy can help treat PTSD in military personnel and veterans. You'll receive the drug during a supervised session, along with talk therapy, to see if it reduces PTSD symptoms.
This study tests whether combining MDMA with talk therapy can help people with post-traumatic stress disorder (PTSD) from war experiences. It involves both individual and group therapy sessions, and the medication is given during some sessions.
Hear when a new PTSD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.